Fosaprepitant – USA

Fosaprepitant – USA

IPR decision: Apr. 20, 2020

AIA Review #
Filing Date
Institution Date
Petitioner
Patent
Respondent
Status
IPR2019-01446
08/01/2019
01/31/2020
Nevakar, Inc.
9,913,853
Cipla
Terminated-Dismissed
US 9,913,853 (Cipla Ltd.; Exp: 11/3/2036)

1. A liquid composition comprising fosaprepitant or a salt thereof and at least one liquid excipient, wherein after storage at 2-8.degree. C. for at least 1 month, aprepitant is present in an amount concentration of no more than 10%, wherein the composition is ready-to-use or ready-to-dilute.

17. A liquid pharmaceutical composition comprising: a) fosaprepitant dimeglumine in an amount from 50-250 mg; b) at least one salt of ethylenediaminetetraacetic acid in an amount from 10-100 mg; c) albumin in an amount from 250 mg-100 g; and d) water in an amount from 3-300 ml.

20. A liquid pharmaceutical composition comprising: a) fosaprepitant dimeglumine in an amount from 50-250 mg; and b) at least one solubilizer in an amount from 1-5 ml.

Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved